Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 48-55

  Mease, P J ^a   Fleischmann, R ^b   Deodhar, A A ^c   Wollenhaupt, J ^d   Khraishi, M ^e   Kielar, D ^f   Woltering, F ^f   Stach, C ^f   Hoepken, B ^f   Arledge, T ^f   Van Der Heijde, D ^g  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Schoen Klinik   (Germany)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f UCB PHARMA   (Belgium)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DACTYLITIS; DIARRHEA; DISEASE ACTIVITY SCORE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; LIVER DISEASE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAIL DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SYMPTOMATOLOGY; UTERINE CERVIX CARCINOMA;

ANTI-TNF; PSORIATIC ARTHRITIS; TREATMENT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PLACEBOS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 84889668023     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203696     Document Type: Article

References (34)

1. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013;72:736-40.
2. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist- diagnosed psoriatic arthritis in psoriasis patients in European/North American dermatology clinics. J Am Acad Dermatol 2013 In press.
3. Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42:1460-68. (Pubitemid 37508919)
4. Alonso JCT, Perez AR, Castrillo JMA, et al. Psoriatic athritis (PA): a clinical, immunological and radiological study of 180 patients. Rheumatology (Oxford) 1991;30:245-50.
5. Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-9.
6. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64(Suppl 2):ii26-9. (Pubitemid 40288516)
7. Partsch G, Wagner E, Leeb BF, et al. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis 1998;57:691-3. (Pubitemid 28558975)
8. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90. (Pubitemid 30487495)
9. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
10. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36. (Pubitemid 40530131)
11. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319-26.
12. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89. (Pubitemid 41447111)
13. Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797.
14. Keystone E, van der Heijde D, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
15. Weinblatt M, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the phase IIIb REALISTIC study. Rheumatology (Oxford) 2012;51:2204-14.
16. Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab0 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 2012;167:180-90.
17. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
18. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38: 727-35.
19. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. (Pubitemid 10164318)
20. van der Heijde D, Sharp J, Wassenberg S, et al. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005;64(Suppl 2):ii61-4. (Pubitemid 40288525)
21. van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: the RAPID-PsA 24-week phase 3 double-blind randomized placebo-controlled study of certolizumab pegol. Ann Rheum Dis 2014;73: 233-7.
22. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-44. (Pubitemid 8387357)
23. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res 2011;63(Suppl 11):S64-85.
24. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum 1996;39:2013-20.
25. Cassell SE, Bieber JD, Rich P, et al. The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007;34:123-9. (Pubitemid 46106572)
26. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69: 48-53.
27. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965-69.
28. Coates LC, Cook R, Lee K-A, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res 2010;62:970-76.
29. EMA. Annex 1: Summary of Product Characteristics (Humira). 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000481/WC500050870.pdf (accessed Feb 2013).
30. Wilson E. Probable inference, the law of succession, and statistical inference. J Am Stat Association 1927;22:209-12.
31. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-57. (Pubitemid 41113349)
32. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368-77.
33. Glintborg B. Clinical response, drug survival and predictors thereof among 548 switchers of tumor necrosis factor alpha inhibitor therapy in psoriatic arthritis. Results from the Danish Nationwide Danbio Registry (abstract). Arthritis Rheum 2012;64(10 (Suppl)):S1081.
34. Ritchlin CT, Gottlieb AB, McInnes IB, et al. Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study. Arthritis Rheum 2012;64(10 (Suppl)):1080-81.